KDIGO 2025 IgA guidelines - Visual Abstract

KDIGO 2025 is here. IgAN management is evolving with precision risk tools, new therapies, and a stronger focus on kidney protection.

Check out the visual abstract created by Natalia Nombera

View fullsize

Guías KDIGO 2025 IgA - El Resumen Visual

Las guías KDIGO 2025 están aquí. El manejo de la nefropatía por IgA (NIgA) está evolucionando con herramientas de estratificación de riesgo más precisas, nuevas terapias y un enfoque más sólido en la protección renal a lo largo de la vida.

Revisa el resumen visual creado por Natalia Nombera

View fullsize

The NeflgArd Part B Visual Abstract

Does targeted-release formulation of Budesonide improve kidney function in primary IgA Nephropathy? Check out the VA by NSMC Intern Anant Pilawan on NefIgArd part B trial

View fullsize

🤔 GWAS in IgA Nephropathy

Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy (Kiryluk, Nature Genetics 2023)

🤔 Sibeprenlimab in IgA Nephropathy

A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy (Mathur, NEJM 2024)

PROTECT study on Sparsentan in IgAN - Visual Abstract

Is Sparsentan effective and safe for patients with IgAN on maximal Raas blockade? Check out the VA by NSMC intern Saumya Vishnoi

View fullsize

More options for immunosuppression in IgA....

Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?

Welcome to #TenTweetNephJC!

✳️10 tweets #NephJC catch-up ✳️

On 3/28-29, #NephJC reviewed the MAIN trial (Mycophenolate monotherapy in IgA Nephropathy). Here are some pearls from the chat ⬇️ pic.twitter.com/RUepFSEwXx

— Nephrology Journal Club (@NephJC) April 28, 2023

Mycophenolate in IgAN - The Visual Abstract

Visual abstract for utility of MMF in IgAN by NSMC intern Dr Jeyakumar Meyyappan

View fullsize

IgA and steroids: the saga continues

Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial

#TenTweetNephJC returns in 2023! Catch-up rapidly with the biggest trials in nephrology.

Up first is NefIgArd.

We all say we hate steroids, but really we love their efficacy but hate their side-effects, right?

IgA nephropathy is again the subject of a steroid trial🧵 pic.twitter.com/sh0xtKPhsP

— Nephrology Journal Club (@NephJC) January 20, 2023

NefIgArd trial : Visual Abstract

Check out the Delightful Visual Abstract for the NefIgArd trial by Priti Meena

Ten Tweets does TESTING 2.0

Did you miss the TESTING reboot discussion? No worries, we have you covered here:

Welcome to #TenTweetNephJC where we will be discussing the largest randomized, placebo controlled trial of steroid treatment in IgA nephropathy patients.
✳️ 10 tweets #NephJC catch-up ✳️ pic.twitter.com/kRdt91F8gq

— Nephrology Jrnl Club (@NephJC) June 21, 2022